Brief: Zivo Bioscience Initiates 42-Day Validation Study With Immune-Modulating Product
30/10/2023 12:33
Oct 30 (Reuters) - Zivo Bioscience Inc ZIVO.O :
* ZIVO BIOSCIENCE INITIATES 42-DAY VALIDATION STUDY WITH
IMMUNE-MODULATING PRODUCT FOR THE PREVENTION AND TREATMENT OF
COCCIDIOSIS IN BROILER CHICKENS
Source text for Eikon: ID:nBw8fjFzta
Further company coverage: ZIVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zivo Bioscience
See all newsBrief: Zivo Bioscience Plans New Study With University Of Delaware To Combat Avian Influenza In Poultry
Brief: Zivo Bioscience Reports Preliminary Efficacy Of Its Proprietary Active Ingredients In Battle Against Avian Influenza
Brief: Zivo Bioscience Initiates 42-Day Validation Study With Immune-Modulating Product
Brief: Zivo Bioscience Announces Reverse Stock Split
Brief: Trial Results Confirm Efficacy Of Zivo Bioscience’S Non-Antibiotic Product Candidate For The Prevention And Treatment Of Coccidiosis In Broiler Chickens